Merus

Merus

Merus

Merus is focused on the use of two proprietary technologies to build a pipeline of innovative human therapeutic antibodies: the OligoclonicsTM and MeMoTM Technologies.
Raised
$55M
Follow us
Alexa global traffic share
Latest funding
$55,000,000
IPO - 2016
Team Size
10+
Employees
TechCrunch

Ask A VC: Merus Capital's Sean Dempsey On The Role Of Corp Dev And More